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Conclusion. These findings demonstrate that HMG-CoA re-Extracellular signal-regulated kinase inhibition by statins in-
ductase inhibitors decrease respiratory burst activity of humanhibits neutrophil activation by ANCA.
PMN in response to ANCA. This effect was independent ofBackround. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-
mevalonate, but involved inhibition of ERK activation duringCoA) reductase inhibitors (statins) may modulate cellular in-
TNF- priming. Our data suggest that HMG-CoA reductaseflammatory functions independent of serum cholesterol. We
inhibitors may help limit inflammatory responses.tested the hypothesis that statins decrease respiratory burst
activity of human polymorphonuclear neutrophils (PMN) in
response to anti-neutrophil cytoplasmic antibodies (ANCA).
Methods. Neutrophils were isolated from healthy human
Anti-neutrophil cytoplasmic antibodies (ANCA) arevolunteers, human immunoglobulins were isolated from pa-
found in microscopic polyangiitis, Wegener’s granuloma-tients with proteinase-3 (PR3)- and myeloperoxidase (MPO)-
ANCA. Superoxide generation was measured by the ferricyto- tosis, Churg-Strauss syndrome, and pauci-immune necro-
chrome C assay and the nitro blue tetrazolium (NBT) test. tizing crescentic glomerulonephritis [1, 2]. ANCA activate
ANCA antigen expression was measured by flow cytometry tumor necrosis factor- (TNF-)-treated polymorpho-
and phosphorylation of mitogen-activated protein kinase
nuclear neutrophils (PMN), leading to respiratory burst(MAPK) was assessed by Western blotting.
and degranulation that may play a key role in the patho-Results. Cerivastatin and simvastatin inhibited respiratory
burst activity to ANCA dose-dependently (1 to 25 mol/L). genesis of vasculitic inflammation [3, 4]. Intracellular
Tumor necrosis factor- (TNF-)-primed neutrophils released pathways controlling both TNF-–mediated priming and
26.7  2.8 nmol O2 /0.75  106 PMN/45 min and 10 mol/L ANCA-mediated activation of neutrophils are incom-
simvastatin reduced this amount to 18.0 2.1 nmol. The inhibi-
pletely defined. Currently, corticosteroids and immuno-tory effect was confirmed by the NBT test. The respiratory
suppressive agents are given to treat ANCA vasculitis;burst decrease could not be reversed by 500 mol/L mevalonic
acid (MVA). In this assay, both statins also inhibited the re- however, better understanding of intracellular pathways
sponse to human ANCA. PR3-ANCA resulted in 19.4  2.0 controlling ANCA-induced inflammation may result in
nmol O2 nmol. This amount was decreased to 6.0  1.2 nmol less toxic therapies. 3-Hydroxy-3-methylglutaryl coen-
by preincubation with 10 mol/L simvastatin (P  0.01). For
zyme A (HMG-CoA) reductase inhibitors (statins) areMPO-ANCA, the values were 22.6  2.8 nmol for controls
widely used to reduce low-density lipoprotein (LDL)-versus 16.7  3.1 nmol with statin (P  0.01). By FACS,
simvastatin decreased TNF-–mediated ANCA antigen trans- cholesterol and to prevent atherosclerosis [5–8]. Interest-
location (from 219  33 to 180  35 MFI for PR3 and 24.0  ingly, numerous reports suggest that statins have effects
2.4 to 18.3 1.1 for MPO). Finally, since p38 MAPK and ERK independent of their cholesterol lowering ability. Forcontrol TNF- priming, we studied the effects of both statins
example, statins decrease C-reactive protein (CRP) inde-on MAPK. Western blotting showed that statins inhibited
pendent of LDL levels [9–11] and reduce angiotensin IITNF-–induced ERK phosphorylation in a dose dependent
fashion, but had no effect on p38. (Ang II)-induced renal injury [12]. Dunzendorfer et al
showed an inhibitory effect on neutrophil chemotaxis
and transmigration with pravastatin [13]. Pravastatin also
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supressed superoxide generation in neutrophils in re-hydroxy-3-methylglutaryl coenzyme A, superoxide, signal transduc-
tion, mitogen-activated protein kinases, respiratory burst. sponse to fMLP through inhibition of tyrosine phosphor-
ylation [14]. Inflammatory processes can trigger diseaseReceived for publication March 28, 2002
activity in ANCA-associated vasculitis [15, 16]. Trimeth-and in revised form July 5, 2002
Accepted for publication August 15, 2002 oprim-sulfamethoxazole prolongs remission in patients
positive for Staphyloccocus aureus [17]. We considered 2003 by the International Society of Nephrology
96
Choi et al: ERK, statins, and ANCA 97
an alternative strategy to stem inflammation. The aim of centage of PMN in the suspension was95% by Wright-
Giemsa staining and by light microscopy.this study was to investigate the effect of statins on human
neutrophil activation by ANCA. We tested the hypothe-
Preparation of immunoglobulinssis that statins decrease the respiratory burst activity.
Human PR3-ANCA sera from six patients with Weg-
ener’s granulomatosis, MPO-ANCA sera from two pa-
METHODS tients with microscopic polyangiitis, and sera from two
Materials healthy individuals were used for the isolation of human
immunoglobulins. Sera were filtered through a 0.2-mmRecombinant TNF- was obtained from Genzyme
syringe filter (Schleicher & Schuell, Duesseldorf, Ger-(Ru¨sselsheim, Germany), SB203580, and PD98059 were
many), were treated with equal volumes of 20 mmol/Lpurchased from Calbiochem (Bad Soden, Germany). Fi-
sodium phosphate buffer, pH 7.0 (binding buffer) andcoll-Hypaque, phorbol myristate acetate (PMA), ferricyto-
applied to a protein G affinity column. The column waschrome C, bovine erythrocyte superoxide dismutase (SOD;
prepared from protein G Sepharose 4 Fast Flow (Phar-2500 to 7000 U/mg protein), cytochalasin, propidium iodide
macia, Uppsala, Sweden) connected to FPLC (Phar-and nitroblue tetrazolium were from Sigma (Deisen-
macia). Bound immunoglobulin were eluted with 0.1hofen, Germany). The polyclonal rabbit antibodies to tyro-
mol/L glycine-HCl buffer, pH 2.75 (elution buffer). Aftersinphosphorylated mitogen-activated protein kinase (p38-
the antibodies emerged from the column, the pH wasMAPK) and extracellular signal-regulated kinase (ERK)
immediately adjusted to 7.0 by using 1 mol/L Tris-HCl,were obtained from New England Biolabs, Inc. (Beverly,
pH 9.0. The protein concentration of the antibodies wasMA, USA), horseradish peroxidase-labeled donkey anti-
measured using the Coomassie protein assay (Pierce, Rock-rabbit IgG was from Amersham (Braunschweig, Ger-
ford, IL, USA). A mouse monoclonal to MPO (MPO-7,many), and FITC-conjugated F(ab)2-fragment of goat
IgG1k) and an isotype-matched control (IgG1k) wereanti-mouse IgG was from Dako (Hamburg, Germany).
purchased from Dako. A mouse monoclonal anti-PR3Dextran was purchased from Amersham Pharmacia
antibody (CLB, IgG1k) was obtained from HISS (Frei-(Amsterdam, The Netherlands). Hanks balanced salt so-
burg, Germany).lution (HBSS), phosphate-buffered saline (PBS), and
trypan blue were from Seromed (Berlin, Germany). Two
Superoxide production assaydifferent reagents of mevalonic acid lactone (mevalonic
acid lactone 97% and DL-mevalonic acid lactone) were Superoxide was measured using the standard assay of
purchased from Sigma and Aldrich (Schnelldorf, Ger- superoxide dismutase (SOD; Sigma) inhibitable reduc-
many). According to the manufacturer’s instructions, tion of ferricytochrome C (Sigma) as described earlier
mevalonic acid lactone from Aldrich was dissolved in [18]. Briefly, PMN were treated with 5 g/mL cytocha-
0.1 mol/L sodium hydroxide to convert the lactone into lasin B (Sigma) for 15 minutes at 4C. Cells (0.75 
sodium mevalonic acid. The product was heated at 50C 106) when indicated were preincubated with different
for two hours. Cerivastatin was a gift from Bayer (Wup- concentrations of cerivastatin or simvastatin and/or mev-
pertal, Germany). Simvastatin was purchased from Cal- alonic acid for 30 minute on ice prior to incubation with
biochem. The inactive form of simvastatin was converted 2 ng/mL TNF- for 15 minutes at 37C (priming). Mono-
with ethanol/0.1 N NaOH, heated for two hours at 50C, clonal antibody to MPO, human ANCA, control anti-
and stored at 4C up to two weeks. The 96-well microtiter body preparations, and PMA were added, respectively.
plates were from TPP-Company (Munich, Germany). The final concentrations were 2.5 g/mL monoclonal
Endotoxin-free reagents and plastic disposables were antibody (mAb) to MPO, 100 g/mL for purified IgG
used in all experiments. preparations, and 50 ng/mL PMA. After the mixture was
incubated in 96-well plates at 37C for up to 60 minutes,
Isolation of human neutrophils the absorption of the samples with and without 300 U/mL
SOD was scanned repetitively at 550 nm using a Mi-Polymorphonuclear neutrophils from healthy human
croplate Autoreader (Molecular Devices, Sunnyvale,volunteers were isolated from heparinized whole blood
by red blood cell sedimentation with 1% dextran, fol- CA, USA). All samples were set up in duplicates. Given
the one-to-one molar stoichiometry, the amount of gen-lowed by Ficoll-Hypaque density gradient centrifugation
and hypotonic lysis of erythrocytes for 15 seconds using erated oxygen superoxide was calculated from the amount
of reduced ferricytochrome C, and the results were ex-sodium chloride solution. PMN were centrifuged (10
minutes at 1050 rpm) and resuspended in HBSS with pressed in nmol O2 /0.75  106 PMN/45 min. No activat-
ing effect was seen when human and mouse control anti-calcium and magnesium (HBSS		). The cell viability
was detected in every cell preparation by trypan blue bodies were used or when cells were primed with 2 ng/mL
TNF-.exclusion and found to be greater than 99%. The per-
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Nitro blue tetrazolium test for one minute at 4C, and pellets were resuspended into
cells lysates with 20 L of ice-cold lysing buffer. TheThe nitro blue tetrazolium (NBT) test was done addi-
buffer consisted of 20 mmol/L Tris-HCl (pH 8.0) con-tionally to measure the generation of reactive oxygen
taining 138 mmol/L NaCl, 1% Triton X-100, 2 mmol/Lradicals. NBT is an electron acceptor used to detect
ethylenediaminetetraacetate (EDTA), 10% glycerol, 0.2indirectly the production of superoxide by stimulated
mmol/L sodium orthovanadate, 1 mmol/L phenylmethyl-PMN. Through reduction yellow, soluble NBT is con-
sulfonyl fluoride (PMSF), 10 g/mL aprotinin, 10 g/mLverted to blue-black formazan, an insoluble material that
leupeptin, 0.1 mmol/L quercetin, and 5 mmol/L iodoacet-precipitates intracellularly. PMN (6  106) were treated
amide. Samples were kept on ice for five minutes, super-with 5 g/mL cytochalasin B for 15 minutes at 4C and
natant was recovered by centrifugation at 13,000  gmixed with 0.2% NBT (in saline). Cells were either stim-
ulated with 50 ng/mL PMA for 25 minutes as a positive for five minutes at 4C, and protein concentration was
control or pretreated with 10 mol/L cerivastatin and measured by BCA protein assay (Pierce, Munich, Ger-
simvastatin for 30 minutes on ice. The stimulation was many). Loading buffer [250 mmol/L Tris-HCl, pH 6.8
followed by 2 ng/mL TNF- priming for 15 minutes and with 4% sodium dodecyl sulfate (SDS), 20% glycerol,
2.5 g/mL mAb to MPO activation for 45 minutes at 0.01% bromphenol blue, 6% 
-mercaptoethanol] was
37C. Respiratory burst activity was evaluated under a added and samples were heated for five minutes at 95C.
light microscope, 100 PMN were counted and the per- Each sample containing 30g protein per lane was loaded
centage that reduced NBT was recorded in five indepen- on 10% SDS-polyacrylamide gel, electrophoresed, and
dent experiments. transferred to nitrocellulose membranes. The membranes
were blocked in TBS-T	BSA 5% for one hour and in-
Assessment of ANCA-antigen expression by cubated overnight with either an antibody to phospho-
flow cytometry
ERK1/2 or to phospho-p38 (1:1000 dilution). Membranes
Fluorescence-activated cell sorter (FACS) flow was were washed and incubated with a secondary antibody,
used as described previously [19] to evaluate the effect horseradish peroxidase-labeled donkey anti-rabbit IgG
of cerivastatin and simvastatin on PR3 and MPO expres- (1:5000). Blot was developed by incubation in a chemilu-
sion on neutrophils. Cells were preincubated for 30 min- minescence substrate (ECL; Amersham) and exposed to
utes on ice with 10 mol/L of the inhibitors or buffer an x-ray film. Equal loading of protein was confirmed by
control, stimulated with 2 ng/mL TNF- or buffer control stripping and reprobing the blots for total p38. Densitom-
for 20 minutes at 37C, and spun down at 300  g for etry of phospho-p38 and phospho-ERK1/2 was performed
six minutes at 4C. In time course studies cells were with scanned x-ray films and the NIH-image program.
preincubated with 10 mol/L of the inhibitors or buffer
control at different time points before or after TNF- as Propidium iodide staining
indicated. In addition, a dose response curve was titrated
Propidium iodide staining of PMN was done by flow
using increasing concentrations of both statins ranging
cytometry to assess necrosis in PMN. Cells (0.75  106)from 1, 5, 10 to 25 mol/L. Pellets were resuspended in
were primed by 2 ng/mL TNF- for 15 minutes and1 mL ice-cold PBS/0.5% paraformaldehyde and stored
activated by 2.5 mg/mL mAb to MPO for 60 minutes aton ice for 20 minutes. Cells were pelleted again and
37C with or without pretreatment with 25 and 50mol/Lresuspended in HBSS without Ca2	/Mg2	 before they
cerivastatin or simvastatin. One sample was treated withwere incubated with dilutions of mAb to PR3, MPO,
cerivastatin alone without further stimulation. One houror an isotype control followed by a secondary FITC-
after the addition of mAb, MPO cells were spun downconjugated F(ab)2-fragment of goat anti-mouse IgG.
at 200  g for five minutes at 4C and resuspended inFlow cytometry was performed on the same day using
PBS containing 2.5 g/mL propidium iodide. Cells werea FACScan (Becton Dickinson, Heidelberg, Germany),
kept at room temperature for five minutes and wereand 10,000 events per sample were collected.
immediately analyzed using a FACscan. Ten thousand
Western blot analysis for p38 MAPK and ERK events per sample were collected using unfixed cells;
positive staining with propidium iodide indicated lossPolymorphonuclear neutrophils (5  106) were pre-
of membrane integrity and cells were considered to betreated for 30 minutes on ice with 25 mol/L simvastatin,
necrotic.25 and 50 mol/L cerivastatin, the p38-MAPK inhibitor
(SB202190), and the ERK-inhibitor (PD98059), respec-
Statistical analysistively. Cells were stimulated with 2 ng/mL TNF-, iso-
Data are given as mean values  SEM. The Studenttype control, and buffer control for 15 minutes at 37C.
t test was done to analyze two groups. Differences wereCells were harvested at the indicated time points. The
activation was stopped with centrifugation at 8,000 rpm considered to be significant when the P value was 0.05.
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34.7  3.8 with NaOH/ethanol pretreatment; N  3).
To exclude toxic effects of the statins, a cell viability
assay was performed with the highest concentration of
cerivastatin and simvastatin (25 and 50 mol/L, respec-
tively). Employing flow cytometry on propidium iodide
stained unfixed cells, we observed a cell viability of 97%
in cells with or without ANCA activation and with or
without statin pretreatment (N  5, data not shown).
Thus, no toxic effect of HMG-CoA reductase inhibitors
could be observed.
The NBT test was used to assess the respiratory burst
by a second, independent method. Figure 2 shows repre-
sentative pictures of five independent experiments with
10mol/L cerivastatin and simvastatin, respectively. Un-
stimulated cells showed no relevant conversion to blue-
black formazan, indicating that no relevant oxygen me-
tabolism occurred (Fig. 2A). PMA stimulated cells served
as a positive control (Fig. 2B); 95 3% of the cells reduced
NBT. TNF- primed cells activated by ANCA showed
a reduction to 72  16% (Fig. 2C) that was reduced to
10  6% by pretreatment with 10 mol/L cerivastatin
(Fig. 2D) and to 10  6% with 10 mol/L simvastatin.
The different conditions were tested in parallel and the
corresponding statistical analysis is depicted in Figure
2E. These results confirm the ferricytochrome C reduction
assay, indicating that both cerivastatin and simvastatin
abrogate respiratory burst activity in neutrophils primed
with TNF- and activated by an mAb to human MPO.
We next investigated whether the inhibitory effect of
Fig. 1. Concentration-dependent effect of cerivastatin (CV) and sim-
HMG-CoA reductase inhibitors also occurred when hu-vastatin (SV) on tumor necrosis factor- (TNF-)-primed neutrophils
stimulated with a monoclonal antibody (mAb) to myeloperoxidase (MPO). man ANCA-preparations were used. For CV, a total of
In parallel experiments, increasing doses of CV (A ) or SV (B ) were 18 experiments were performed with six different PR3-
added 30 minutes prior to priming with 2 ng/mL TNF-. Symbols are:
ANCA preparations (N  12 independent experiments() control; () 1 mol/L; () 5 mol/L; () 10 mol/L; (| ) 25 mol/L.
Seven (CV) or six (SV) independent experiments were done and super- each using different neutrophil donors) and a total of 10
oxide was measured by the continuous ferricytochrome C assay up to experiments were done with two different MPO-ANCA
45 minutes. preparations (N  5 independent studies). For SV, 12
independent experiments were carried out with five dif-
ferent PR3-ANCA preparations and five independentRESULTS
experiments with one MPO-ANCA. Figure 3 indicatesEffect of statins on superoxide production
that preincubation with 10 mol/L cerivastatin or 10
We first investigated the effect of cerivastatin and sim- mol/L simvastatin significantly decreased superoxide
vastatin on TNF- primed neutrophils activated by formation in response to human ANCA. With ceriva-
ANCA. Neutrophils were preincubated with increasing statin, PR3-induced superoxide generation was de-
concentrations of the HMG-CoA reductase inhibitors creased from 20.3  1.7 nmol O2 to 9.1  1.4 nmol and
(1 to 25 mol/L) 30 minutes before priming cells with MPO-induced activation from 22.2  1.3 nmol to 14.5 
TNF- and subsequent activation with an mAb to MPO. 1.7 nmol. For simvastatin these numbers decreased from
Cerivastatin (Fig. 1A) and simvastatin (Fig. 1B) de- 19.4  2.0 nmol to 6.0  1.2 nmol with PR3-ANCA
creased the respiratory burst in a dose and time depen- stimulation and from 22.6 2.8 nmol to 16.7 3.1 nmol
dent manner. Inhibition was already observed at concen- when MPO-ANCA were used. In contrast, no effect was
trations as little as 5 mol/L, and was detected for both seen in PMA-activated neutrophils (49.2  3.7 nmol
the more lipophilic HMG-CoA reductase inhibitor sim- without cerivastatin vs. 49.2 4.4 nmol with cerivastatin
vastatin and the more hydrophilic cerivastatin. Control preincubation, N  5). No significant release of super-
experiments with the combined simvastatin-diluent oxide was seen in cells stimulated with IgG preparations
NaOH/ethanol used at the highest concentration re- from two healthy controls (2.5  0.9 nmol in unstimu-
vealed no effect on anti-MPO–induced superoxide gen- lated cells vs. 2.3  1.0 nmol in TNF--primed and IgG
stimulated PMN, N 13). Pretreatment with 25 mol/Leration (33.3  3.8 nmol O2 /0.75  106 PMN/45 min vs.
Choi et al: ERK, statins, and ANCA100
Fig. 2. Respiratory burst activity in response to a mAb to MPO by CV and SV using nitro blue tetrazolium (NBT). Neutrophils were incubated
for 45 minutes in buffer control (A ), PMA (B ), or stimulated with the mAb to MPO after TNF- priming (C ). TNF- primed cells stimulated
with the mAb to MPO were pretreated with 10 mol/L CV (D ) or 10 mol/L SV (E ). Representative pictures from 5 independent experiments
are shown. (F ) The corresponding statistical analysis. Respiratory burst activity results in a reduction from yellow NBT to blue-black formazan.
This response was inhibited by CV and SV (**P  0.01).
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Fig. 4. Effects of mevalonic acid (MVA) on CV and SV mediatedFig. 3. Effects of 10 mol/L cerivastatin (CV) and 10 mol/L simva-
inhibition of respiratory burst activity were tested in parallel. TNF-–statin (SV) (dotted bars) on superoxide generation of TNF-–primed
primed neutrophils were stimulated with a mAb to MPO without statinneutrophils stimulated with human PR3-ANCA (open bars) and MPO-
preincubation (, N  7 independent experiments), with 10 mol/LANCA (gray bars) was tested. For CV, a total of 18 experiments with
CV preincubation ( , N  7) or with 10 mol/L SV preincubation (,six different PR3-ANCA preparations and a total of 10 experiments
N  6) in the presence or absence of 500 mol/L MVA. Superoxidewith two different MPO-ANCA preparations were performed. For SV,
formation was measured using the continuous ferricytochrome C assay,12 experiments with five different PR3-ANCA preparations and 5 ex-
and results are shown for the 45-minute time point. These results showperiments with one MPO-ANCA were carried out. Superoxide forma-
that both statins inhibit the respiratory burst in a mevalonic acid inde-tion was measured using the continuous ferricytochrome C assay, and
pendent manner (**P 0.01 compared to TNF-–primed cells activatedresults are shown for the 45-minute time point (*P  0.05; **P  0.01).
with the mAb to MPO).
Time-dependencecerivastatin had no effect on the generation of superoxide
in cells stimulated with or without TNF- (from 1.3  To investigate whether cerivastatin affects TNF-
0.3 to 3.0  1.5 nmol O2 in cells without and 2.75  1.4 priming or the subsequent ANCA-stimulation, ceriva-
nmol to 2.75  0.9 nmol with TNF- stimulation, N  statin was given at different time points. Adding 25
3 vs. N 4). These data indicate that statins dose-depen- mol/L of cerivastatin 30 minutes before TNF- or to-
dently inhibited superoxide generation of neutrophils in gether with TNF- during the 15-minute priming period
response to human ANCA in vitro. showed a significant decrease in superoxide release from
24.8  4.0 nmol O2 to 13.6  5.3 nmol and 13.2  5.1
Effects of mevalonic acid nmol (N  5). In contrast, with the addition of ceriva-
To test the effects of cerivastatin and simvastatin on statin 5 or 20 minutes after stimulation with ANCA, no
ANCA-induced superoxide generation in the presence significant inhibitory effect was observed (22.4 4.8 and
of mevalonic acid (MVA), cells were preincubated with 26  3.9 nmol). These data suggest that cerivastatin
each statin in the presence of MVA for 30 minutes, affects the TNF- priming process rather than ANCA-
followed by TNF- priming and activation with the mAb induced signaling events.
to MPO. Figure 4 indicates that the inhibitory effect of
Translocation of ANCA-antigensboth statins was not reversed by 500 mol/L MVA.
These data were confirmed with two human PR3- and The effects of the statins on membrane expression of
two MPO-ANCA preparations in two independent ex- ANCA antigens during TNF- priming were investi-
periments, where both statins again inhibited superoxide gated. Using flow cytometry, in a preliminary time course
generation in an MVA-independent manner. PR3-ANCA study 10 mol/L of the statins were added either 30
induced 13.5 0.8 nmol O2 . This amount was decreased or 5 minutes before TNF, or 5 minutes after TNF. An
to 6.5  0.4 nmol O2 by 10 mol/L cerivastatin, and to inhibitory effect was seen only when cells were preincu-
6.3  1.8 nmol by 10 mol/L simvastatin in the absence bated for 30 minutes, but there was no decrease in ANCA
of 500 mol/L MVA, and to 3.5  0.8 nmol and 6.0  antigen translocation at all other time points (data not
shown). Next, we titrated a dose response curve for both1.2 nmol in the presence of MVA. MPO-ANCA induced
18.3  1.3 nmol O2 , and this number was decreased to cerivastatin and simvastatin ranging from 1, 5, and 10 to
25 mol/L (N  3 for each; Fig. 5 C-F). A typical flow7.5  0.9 nmol O2 by cerivastatin and to 7.5  0.3 nmol
by simvastatin in the absence of 500 mol/L MVA, and cytometry study for PR3 translocation using 10 mol/L
of either cerivastatin (Fig. 5A) or simvastatin (Fig. 5B)to 4.0  1.0 nmol and 8.3  0.5 nmol in the presence of
MVA. Together, these data suggest that the mevalonate- is given also. Based on these results, six independent
experiments were performed that pre-incubated the cellsdependent pathway does not mediate the effect of short-
term incubation with either cerivastatin or simvastatin for 30 minutes with 10mol/L of either statin; and a small
but significant inhibition of PR3- and MPO-translocationon ANCA-induced respiratory burst.
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Fig. 5. Effects of statins on ANCA antigen expression studied by FACS. A typical flow cytometry experiment of the effect of 10 mol/L cerivastatin
(A ) and 10 mol/L simvastatin (B ) on TNF-–induced PR3 translocation is depicted. In these experiments, cells were incubated either with buffer
(), or stimulated with TNF- ( ), or TNF- stimulated cells were preincubated with increasing concentrations of either cerivastatin (CV; ) or
simvastatin (SV; ) prior to TNF- stimulation, respectively. Three independent experiments show a dose dependent inhibition of membrane
translocation of PR3 (C, D) and MPO (E, F ) by both statins.
was observed in response to 2 ng/mL TNF- (Fig. 6). brane expression of ANCA antigens in unstimulated
cells. These data suggest an effect of statins on TNF-–TNF- treated cells showed a mean fluorescence inten-
sity (MFI) for PR3 membrane expression of 234  57, induced ANCA antigen translocation that is mediated,
at least in part, by p38-MAPK, as shown in a previouswhich decreased to 191  51 in cerivastatin pretreated
cells and from 219  33 to 180  35 in simvastatin study [20].
pretreated cells (Fig. 6A). TNF-–induced MPO mem-
Phosphorylation and activation of p38-MAPK and ERKbrane expression decreased from 26.2  5.0 to 14.8 
4.0 by cerivastatin pretreatment and from 24  2.4 to To test the hypothesis that HMG-CoA reductase in-
hibitors use MAPK-pathways, neutrophils were pre-18.3 1.1 in simvastatin-pretreated cells (Fig. 6B). Ceri-
vastatin and simvastatin alone did not affect the mem- treated with simvastatin 25mol/L or two concentrations
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DISCUSSION
This study investigated the effects of the HMG-CoA
reductase inhibitors simvastatin and cerivastatin on the
activation of human neutrophils by ANCA, and tested
the hypothesis that these compounds affect MAP kinase
signaling pathways. Our results show that statins indeed
decreased ANCA-induced respiratory burst activity and
that this effect involved the inhibition of ANCA antigen
translocation during TNF- priming. The effect was in-
dependent of the mevalonate pathway and was due, at
least in part, to inhibition of the MAPK ERK.
Anti-neutrophil cytoplasmic antibody-activated neu-
trophils release a variety of cytotoxic substances, includ-
ing oxygen-derived free radicals, inflammatory cytokines,
and proteases [21]. These events may contribute to the
development of ANCA-associated vasculitis. Treatment
with corticosteroids and cytotoxic agents is effective, but
long-term use is associated with severe side effects. Addi-
tive approaches, such as trimethoprim-sulfamethoxazole,
are aimed to control inflammatory processes that trigger
disease activity [17]. Recently, statins were proposed to
exhibit LDL cholesterol-independent anti-inflammatory
properties. For example, Kanno et al showed that 1 mmol/L
pravastatin inhibited formyl-methionyl-leucyl-phenylal-
anine (fMLP)-induced superoxide generation in PMNFig. 6. Effects of 10 mol/L CV and SV on TNF-–induced PR3 and
MPO membrane expression studied by flow cytometry. Cells incubated when added prior or immediately after treatment with
with buffer control ( ) or without TNF- stimulation () were preincu- fMLP [14]. Dunzendorfer and colleagues failed to showbated with CV () or SV ( ). PR3 (A ) and MPO (B ) membrane
significant effects of up to 200 mol/L pravastatin onexpression was measured in 6 independent experiments (**P  0.01).
These results indicate a small but significant inhibition of ANCA antigen fMLP-triggered respiratory burst activity [13]. In another
expression by both statins. study, cerivastatin inhibited the release of interleukin-8
(IL-8) and MCP-1 in human macrophages and endothe-
lial cells infected with chlamydia pneumoniae and re-
of cerivastatin (25 and 50 mol/L) for 30 minutes and duced superoxide production by 20.4% [22]. Our data
Western blots were performed after stimulation with show that HMG-CoA reductase inhibitors diminish the
TNF-. Figure 7 shows an immunoblot of phosphory- respiratory burst activity in response to ANCA in a dose-
lated ERK (Fig. 7A) with the corresponding densitomet- dependent manner. Inhibition of superoxide production
ric analysis and Figure 8 of phosphorylated p38 MAPK, started at low concentration of 1 mol/L and was signifi-
each from five parallel experiments. Phosphorylated cant at 10 mol/L. This effect was observed for two dif-
ERK and p38 were not detected in freshly isolated neu- ferent statins, simvastatin and cerivastatin, where simva-
trophils, but increased rapidly after priming with TNF-. statin is known to be a more lipophilic and cerivastatin
Preincubation with simvastatin (Fig. 7A) or cerivastatin a more hydrophilic compound [23–25]. Time course stud-
(Fig. 7B) diminished ERK phosphorylation. In Figure
ies suggested that HMG-CoA reductase inhibitors are7A, TNF- treatment resulted in an OD measurement
particularly effective during TNF- priming.of 46  3 and this number was decreased by 30% to
Mevalonate is the product of HMG-CoA reductase,32 3 by pretreatment with simvastatin. The membranes
a major regulatory enzyme of cholesterol biosynthesis.were stripped and reblotted for p38, showing equal pro-
The mevalonate pathway produces isoprenoids that aretein loading (data not shown). Cerivastatin also de-
vital for diverse cellular functions, ranging from choles-creased TNF- induced ERK phosphorylation. Twenty-
terol synthesis to growth control. Studies in leukocytesfive mol/L cerivastatin inhibited by 32% from 75  11
demonstrated that cholesterol synthesis requires severalto 51  5, and by 59% to 31  6 when 50 mol/L were
hours of incubation to become detectable in in vitroused. In contrast, TNF- induced phosphorylation of p38
assays. Pravastatin incubation longer than 12 hours wasMAPK was not affected by simvastatin preincubation
needed to inhibit cholesterol synthesis in monocytes [26].(Fig. 8). These results suggest that statins inhibit activa-
Moreover, neutrophils are unable to produce cholesteroltion of human neutrophils via ERK, but do not affect
the p38-MAPK pathway. in significant amounts [27]. Thus, it is not surprising that
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Fig. 7. Effects of simvastatin (SV) and ceri-
vastatin (CV) on ERK phosphorylation dur-
ing TNF- priming assessed by Western blot-
ting. Cells were either left untreated (Ctrl) or
treated with 2 ng/mL tumor necrosis factor-
(TNF). TNF-–treated cells were preincu-
bated with buffer control, 25 mol/L SV or
50 mol/L PD (PD), respectively (A, N  5);
a representative experiment for simvastatin is
shown. Preincubation also was carried out
with 25 or 50 mol/L cerivastatin; a typical
experiment is given in panel B (N  5). The
corresponding statistical analysis of phosphor-
ylated ERK for (C ) simvastatin and for (D )
cerivastatin (*P  0.05; **P  0.01).
oxidative agents, especially regarding the short-term ef-
fects that are not dependent on the mevalonate pathway.
During TNF-–mediated priming, ANCA antigens
are translocated from cytoplasmic granules to the outer
cell membrane. Here, they are cross-linked by ANCA
initiating full-blown neutrophil activation [19]. In our
study, we observed that simvastatin and cerivastatin de-
creased TNF-–induced translocation of both PR3 and
MPO. Statins affect intracellular pathways in several cell
types. For example, 10 mol/L simvastatin inhibited
platelet-derived growth factor (PDGF)-induced smooth
muscle cell (SMC) DNA synthesis by95% [30], and the
same dose simvastatin decreased the basal transcriptionFig. 8. Effects of simvastatin (SV) on p38 phosphorylation during
TNF- priming assessed by Western blotting. Cells were either left rate of the preproendothelin-1 gene in bovine aortic en-
untreated (Control) or treated with 2 ng/L TNF- (TNF). TNF-–
dothelial cells [31]. Twenty mol/L simvastatin blockedtreated cells were preincubated with buffer control, 25 mol/L SV or
25 mol/L SB (SB) (N  5). A representative experiment is shown. the tyrosine kinase Pyk2 in pulmonary vein endothelial
cells [32]. MAPK also are activated by tyrosine phos-
phorylation. Simvastatin 10 mol/L decreased MAPK
activity in human coronary artery endothelial cells [33].
in our short-term experiments mevalonic acid did not Moreover, pravastatin and lovastatin suppressed the in-
prevent the effect of statins. These data suggest that the crement of MAPK activity in in-vitro-activated mesan-
effect of simvastatin and cerivastatin on ANCA-induced gial cells [34, 35], and cerivastatin almost completely
respiratory burst in human neutrophils is mediated through prevented Ang II-induced ERK phosphorylation in rat
mevalonate-independent pathways. In agreement, Kanno aortic vascular smooth muscle cells [12]. Studies in leuko-
et al reported that mevalonic acid did not prevent the cytic cells using 10mol/L lovastatin demonstrated abro-
pravastatin-mediated inhibition of the respiratory burst gation of ERK phosphorylation in OKT3 stimulated Jur-
in neutrophils [14]. However, statins may display antioxi- kat cells [36]. The importance of tyrosine kinases, and
dant activities. Chen et al showed that lovastatin reduced particularly MAPK during TNF-–mediated priming of
the maximal rate of oxidation induced by leukocytes ANCA-activated human neutrophils was shown pre-
isolated from rabbits and totally blocked the initiation viously by our group [20]. We observed that simvastatin
of LDL in higher amounts, while it had no significant ef- and cerivastatin decreased ERK phosphorylation in re-
fect on plasma cholesterol levels in vivo [28]. Also, sim- sponse to priming concentrations of TNF-. In contrast,
vastatin showed a dose-dependent antioxidant effect on simvastatin did not affect the phosphorylation of p38
LDL and HDL oxidation [29]. These findings suggest a MAPK. The latter finding was somewhat surprising in
the context of the statins’ ability to show a small butpossible role of HMG-CoA reductase inhibitors as anti-
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Force/Texas Coronary Atherosclerosis Prevention Study. JAMAsignificant effect on ANCA antigen translocation during
279:1615–1622, 1998
TNF- priming together with our previous observation 9. Horne BD, Muhlestein JB, Carlquist JF, et al: Statin therapy,
that p38 MAPK controls TNF-–mediated ANCA anti- lipid levels, C-reactive protein and the survival of patients with
angiographically severe coronary artery disease. J Am Coll Cardiolgen translocation. Thus, an additional signaling path-
36:1774–1780, 2000way(s) may control ANCA antigen translocation, and 10. Ikeda U, Ito T, Shimada K: Statins and C-reactive protein. Lancet
should be characterized in future studies. 353:1274–1275, 1999
11. Strandberg TE, Vanhanen H, Tikkanen MJ: Associations be-In conclusion, our data demonstrate that HMG-CoA
tween change in C-reactive protein and serum lipids during statinreductase inhibitors decrease respiratory burst activity in treatment. Ann Med 32:579–583, 2000
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14. Kanno T, Abe K, Yabuki M, et al: Selective inhibition of formyl-
support the hypothesis that statins have anti-inflamma- methionyl-leucyl-phenylalanine (fMLF)-dependent superoxide gen-
eration in neutrophils by pravastatin, an inhibitor of 3-hydroxy-3-tory effects. Clinical application in prospective studies
methylglutaryl coenzyme A (HMG-CoA) reductase. Biochem Phar-may be an additional option for treating patients with
macol 58:1975–1980, 1999
ANCA-associated vasculitis. 15. Stegeman CA, Tervaert JW, Sluiter WJ, et al: Association of
chronic nasal carriage of Staphylococcus aureus and higher relapse
Reprint requests to Ralph Kettritz, M.D., Division of Nephrology, rates in Wegener granulomatosis. Ann Intern Med 120:12–17, 1994
Franz Volhard Clinic, Wiltbergstrasse 50, 13122 Berlin, Germany. 16. Kallenberg CG, Brouwer E, Mulder AH, et al: ANCA–path-
E-mail: kettritz@fvk-berlin.de ophysiology revisited. Clin Exp Immunol 100:1–3, 1995
17. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg
CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the pre-
APPENDIX vention of relapses of Wegener’s granulomatosis. Dutch Co-Tri-
moxazole Wegener Study Group. N Engl J Med 335:16–20, 1996
Abbreviations used in this article are: ANCA, anti-neutrophil cyto- 18. Pick E, Mizel D: Rapid microassays for the measurement of super-
plasmic antibodies; Ang II, angiotensin II; BSA, bovine serum albumin; oxide and hydrogen peroxide production by macrophages in cul-CV, cerivastatin; EDTA, ethylenediaminetetraacetic acid; ERK, ex- ture using an automatic enzyme immunoassay reader. J Immunoltracellular signal-regulated kinase; fMLP, N-formyl-methionyl-leucyl-
Methods 46:211–226, 1981phenylalanine; HBSS, Hank’s balanced salt solution; HMG-CoA,
19. Kettritz R, Jennette JC, Falk RJ: Crosslinking of ANCA-anti-3-hydroxy-3-methylglutaryl coenzyme A; IL, interleukin; LDL, low den-
gens stimulates superoxide release by human neutrophils. J Amsity lipoprotein; mAb, monoclonal antibody; MAPK, mitogen-activated
Soc Nephrol 8:386–394, 1997protein kinase; MFI, mean fluorescence intensity; MPO, myeloperoxi-
20. Kettritz R, Schreiber A, Luft FC, Haller H: Role of mitogen-dase; MVA, mevalonic acid; NBT, nitro blue tetrazolium; PBS, phos-
activated protein kinases in activation of human neutrophils byphate-buffered saline; PDGF, platelet-derived growth factor; PMA,
antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 12:37–phorbol myristate acetate; PMN, polymorphonuclear neutrophil; PR3,
46, 2001proteinase-3; SMC, smooth muscle cells; SOD, superoxide dismutase;
21. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365–SV, simvastatin; TNF-, tumor necrosis factor-.
376, 1989
22. Kothe H, Dalhoff K, Rupp J, et al: Hydroxymethylglutaryl coen-
REFERENCES zyme A reductase inhibitors modify the inflammatory response of
human macrophages and endothelial cells infected with Chlamydia
1. van der Woude FJ, Rasmussen N, Lobatto S, et al: Autoantibod- pneumoniae. Circulation 101:1760–1763, 2000ies against neutrophils and monocytes: Tool for diagnosis and 23. Koga T, Fukuda K, Shimada Y, et al: Tissue selectivity of prava-marker for disease activity in Wegener’s granulomatosis. Lancet
statin sodium, lovastatin and simvastatin. The relationship betweeni:425–429, 1985
inhibition of de novo sterol synthesis and active drug concentra-2. Jennette JC, Falk RJ: Small-vessel vasculitis. N Engl J Med 337:
tions in the liver, spleen and testis in rat. Eur J Biochem 209:315–1512–1523, 1997
319, 19923. Franssen CF, Huitema MG, Muller Kobold AC, et al: In vitro
24. Bischoff H, Angerbauer R, Boberg M, et al: Preclinical reviewneutrophil activation by antibodies to proteinase 3 and myeloper-
of cerivastatin sodium–a step forward in HMG-CoA reductaseoxidase from patients with crescentic glomerulonephritis. J Am
inhibition. Atherosclerosis 139(Suppl 1):S7–S13, 1998Soc Nephrol 10:1506–1515, 1999
25. Boberg M, Angerbauer R, Kanhai WK, et al: Biotransformation4. Falk RJ, Terrell RS, Charles LA, et al: Anti-neutrophil cyto-
of cerivastatin in mice, rats, and dogs in vivo. Drug Metab Disposplasmic autoantibodies induce neutrophils to degranulate and
26:640–652, 1998produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115–
26. Kreuzer J, Bader J, Jahn L, et al: Chemotaxis of the monocyte4119, 1990
cell line U937: Dependence on cholesterol and early mevalonate5. Randomised trial of cholesterol lowering in 4444 patients with
pathway products. Atherosclerosis 90:203–209, 1991coronary heart disease: The Scandinavian Simvastatin Survival
27. Yachnin S, Toub DB, Mannickarottu V: Divergence in choles-Study (4S). Lancet 344:1383–1389, 1994
terol biosynthetic rates and 3-hydroxy-3-methylglutaryl-CoA re-6. Effect of simvastatin on coronary atheroma: The Multicentre Anti-
ductase activity as a consequence of granulocyte versus monocyte-Atheroma Study (MAAS). Lancet 344:633–638, 1994
macrophage differentiation in HL-60 cells. Proc Natl Acad Sci USA7. Influence of pravastatin and plasma lipids on clinical events in
81:894–897, 1984the West of Scotland Coronary Prevention Study (WOSCOPS).
28. Chen L, Haught WH, Yang B, et al: Preservation of endogenousCirculation 97:1440–1445, 1998
antioxidant activity and inhibition of lipid peroxidation as common8. Downs JR, Clearfield M, Weis S, et al: Primary prevention of
mechanisms of antiatherosclerotic effects of vitamin E, lovastatinacute coronary events with lovastatin in men and women with
average cholesterol levels: Results of AFCAPS/TexCAPS. Air and amlodipine. J Am Coll Cardiol 30:569–575, 1997
Choi et al: ERK, statins, and ANCA106
29. Girona J, La Ville AE, Sola R, et al: Simvastatin decreases alde- cells. Involvement of geranylgeranylation of small G protein Rap1.
J Biol Chem 276:15761–15767, 2001hyde production derived from lipoprotein oxidation. Am J Cardiol
83:846–851, 1999 33. Mehta JL, Li DY, Chen HJ, et al: Inhibition of LOX-1 by statins
may relate to upregulation of eNOS. Biochem Biophys Res Com-30. Laufs U, Marra D, Node K, Liao JK: 3-Hydroxy-3-methylglu-
taryl-CoA reductase inhibitors attenuate vascular smooth muscle mun 289:857–861, 2001
34. Yokota T, Utsunomiya K, Murakawa Y, et al: Mechanism ofproliferation by preventing rho GTPase-induced down-regulation
of p27(Kip1). J Biol Chem 274:21926–21931, 1999 preventive effect of HMG-CoA reductase inhibitor on diabetic
nephropathy. Kidney Int 56(Suppl 71):S178–S181, 199931. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S: Involve-
ment of Rho GTPases in the transcriptional inhibition of prepro- 35. Bassa BV, Roh DD, Vaziri ND, et al: Effect of inhibition of
cholesterol synthetic pathway on the activation of Ras and MAPendothelin-1 gene expression by simvastatin in vascular endothelial
cells. Circ Res 87:616–622, 2000 kinase in mesangial cells. Biochim Biophys Acta 1449:137–149, 1999
36. Goldman F, Hohl RJ, Crabtree J, et al: Lovastatin inhibits T-cell32. Satoh K, Ichihara K, Landon EJ, et al: 3-Hydroxy-3-methylglu-
taryl-CoA reductase inhibitors block calcium-dependent tyrosine antigen receptor signaling independent of its effects on ras. Blood
88:4611–4619, 1996kinase Pyk2 activation by angiotensin II in vascular endothelial
